The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’View Video
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin AmericaView Video

Latest Share Chat

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 48.85
Bid: 48.60
Ask: 48.70
Change: 1.60 (3.39%)
Spread: 0.10 (0.206%)
Open: 47.55
High: 49.55
Low: 47.55
Prev. Close: 47.25
IPO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Top 20 portfolio company funding round

22 Dec 2023 07:10

RNS Number : 7581X
IP Group PLC
22 December 2023
 

FOR RELEASE ON

22 December 2023

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE UK VERSION OF THE MARKET ABUSE REGULATION (EU NO. 596/2014) WHICH FORMS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018.

 

IP Group plc - Top 20 portfolio company funding round

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group"), which invests in breakthrough science and innovation companies with the potential to create a better future for all, notes its participation today in a follow-on portfolio company funding round, for which it anticipates recording a net unrealised fair value gain of approximately £40m* or 4p per share.

IP Group has committed a total of US$15m (£11.8m*) to the funding round. Completion of the transaction is subject to certain conditions and is due to occur in mid-January 2024. Further information on the funding round, which has been supported by both existing and new investors, will be provided in due course.

The Group's directors are currently reviewing the carrying values of all assets in the portfolio as part of the usual year-end process. While it is too early to provide guidance as to the carrying values of the Group's portfolio companies, they currently anticipate that the gain relating to this investment will be offset by other fair value reductions in the portfolio. 

*GBP equivalent using 1.26 USD/GBP

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Liz Vaughan-Adams, Communications

+44 (0) 20 7444 0062/+44 (0) 7967 312125

Portland

Vic Wallin

Alex Donaldson

+44 (0) 7973 823119

+44 (0) 7516 729702

 

Notes for editors

 

About IP Group

 

IP Group accelerates the impact of science for a better future. Athe most active UK based, early stage science investorwe develop and support some of the world's most exciting businesses in deeptech, life sciences and cleantech (led by Kiko Ventures). Through Parkwalk, the UK's largest growth EIS fund manager, we also back world-changing innovation emerging in leading universities and research institutionsOur specialist investment team combines sector expertise with an international approach. Together we have a strong track record of success, having backed high-profile companies including Oxford Nanopore Technologies plc, First Light Fusion, Hysata, and Oxa. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO. For more information, please visit our website at www.ipgroupplc.com.

 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDTTBRTMTMTMFJ
Date   Source Headline
26th Apr 20245:29 pmRNSTransaction in Own Shares
26th Apr 20243:36 pmRNSEmployee Share Schemes; Director/PDMR shareholding
26th Apr 20247:00 amRNSTransaction in Own Shares
25th Apr 20247:00 amRNSTransaction in Own Shares
24th Apr 20247:00 amRNSTransaction in Own Shares
23rd Apr 20246:05 pmRNSNotice of AGM, Annual Report
23rd Apr 20247:00 amRNSTransaction in Own Shares
22nd Apr 20247:00 amRNSTransaction in Own Shares
19th Apr 20247:00 amRNSTransaction in Own Shares
18th Apr 20247:00 amRNSTransaction in Own Shares
16th Apr 20245:48 pmRNSTransaction in Own Shares
16th Apr 20247:00 amRNSTransaction in Own Shares
15th Apr 20247:00 amRNSTransaction in Own Shares
12th Apr 20247:00 amRNSTransaction in Own Shares
10th Apr 20245:56 pmRNSTransaction in Own Shares
9th Apr 20245:31 pmRNSTransaction in Own Shares
8th Apr 20245:32 pmRNSTransaction in Own Shares
8th Apr 20247:00 amRNSTransaction in Own Shares
4th Apr 20245:27 pmRNSTransaction in Own Shares
3rd Apr 20245:37 pmRNSTransaction in Own Shares
3rd Apr 20247:00 amRNSTransaction in Own Shares
2nd Apr 20247:00 amRNSTotal Voting Rights
2nd Apr 20247:00 amRNSTransaction in Own Shares
28th Mar 20247:00 amRNSTransaction in Own Shares
26th Mar 20245:30 pmRNSTransaction in Own Shares
25th Mar 20246:03 pmRNSTransaction in Own Shares
25th Mar 20248:54 amRNSDirector Declaration
25th Mar 20247:00 amRNSTransaction in Own Shares
22nd Mar 20247:00 amRNSTransaction in Own Shares
21st Mar 20247:00 amRNSTransaction in Own Shares
18th Mar 20245:56 pmRNSTransaction in Own Shares
18th Mar 20247:00 amRNSTransaction in Own Shares
15th Mar 20245:03 pmRNSDirector Declaration
15th Mar 20247:00 amRNSTransaction in Own Shares
14th Mar 20247:00 amRNSTransaction in Own Shares
13th Mar 20247:00 amRNS2023 Annual Results
12th Mar 20245:24 pmRNSTransaction in Own Shares
12th Mar 20247:00 amRNSTransaction in Own Shares
11th Mar 20247:00 amRNSCorrection - Holding(s) in Company
11th Mar 20247:00 amRNSTransaction in Own Shares
8th Mar 20242:35 pmRNSHolding(s) in Company
8th Mar 20247:00 amRNSTransaction in Own Shares
7th Mar 20247:00 amRNSTransaction in Own Shares
5th Mar 20245:02 pmRNSTransaction in Own Shares
4th Mar 20245:34 pmRNSTransaction in Own Shares
4th Mar 20247:00 amRNSTransaction in Own Shares
1st Mar 20247:00 amRNSTotal Voting Rights
1st Mar 20247:00 amRNSTransaction in Own Shares
29th Feb 20247:00 amRNSTransaction in Own Shares
28th Feb 20249:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.